MRNA vaccines take on glioblastoma: a new hope against brain cancer recurrence?

NCT ID NCT07520214

ENROLLING_BY_INVITATION Disease control Sponsor: Beijing Neurosurgical Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests two mRNA vaccines, GV-907 and GV-108, in 9 adults with a specific type of glioblastoma. The goal is to see if the vaccines are safe and can trigger an immune response to prevent the cancer from coming back after standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA vaccines GV-907 and GV-108
What this could lead to: If successful, this could point toward a new way to delay or prevent glioblastoma recurrence using personalized mRNA vaccines.
What could go wrong: This is a very early, small trial with only 9 participants, so results may not apply broadly. The vaccines may not trigger a strong enough immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOM WHO GRADE 4 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IDH-wildtype glioblastoma glioblastoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOM WHO GRADE 4 GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE

Contacts and locations

Locations

Beijing Tiantan Hospital

Beijing, Beijing Municipality, 100050, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.